Roivant Sciences Stock Today
| ROIV Stock | USD 11.82 0.33 2.87% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Roivant Sciences is selling for under 11.82 as of the 21st of November 2024; that is 2.87 percent increase since the beginning of the trading day. The stock's lowest day price was 11.62. Roivant Sciences has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Roivant Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of October 2021 | Category Healthcare | Classification Health Care |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 727.95 M outstanding shares of which 46.57 M shares are at this time shorted by private and institutional investors with about 11.66 trading days to cover. More on Roivant Sciences
Moving against Roivant Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Roivant Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President COO | PharmD MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsRoivant Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Roivant Sciences' financial leverage. It provides some insight into what part of Roivant Sciences' total assets is financed by creditors.
| |||||
Roivant Sciences (ROIV) is traded on NASDAQ Exchange in USA. It is located in 50 Broadway, London, United Kingdom, SW1H 0DB and employs 908 people. Roivant Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.36 B. Roivant Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 727.95 M outstanding shares of which 46.57 M shares are at this time shorted by private and institutional investors with about 11.66 trading days to cover.
Roivant Sciences currently holds about 1.94 B in cash with (765.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Roivant Sciences Probability Of Bankruptcy
Ownership AllocationRoivant Sciences owns a total of 727.95 Million outstanding shares. The majority of Roivant Sciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Roivant Sciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Roivant Sciences. Please pay attention to any change in the institutional holdings of Roivant Sciences as this could imply that something significant has changed or is about to change at the company. Also note that almost sixty-five million five hundred fifteen thousand five hundred one invesors are currently shorting Roivant Sciences expressing very little confidence in its future performance.
Check Roivant Ownership Details
Roivant Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-06-30 | 8 M | |
| Geode Capital Management, Llc | 2024-06-30 | 6.3 M | |
| Amvescap Plc. | 2024-06-30 | 5.9 M | |
| Anchorage Advisors, Llc | 2024-06-30 | 4.8 M | |
| Pointstate Capital Lp | 2024-06-30 | 4.5 M | |
| Norges Bank | 2024-06-30 | 4.2 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 4.2 M | |
| Adar1 Capital Management Llc | 2024-06-30 | 4.2 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 3.9 M | |
| Viking Global Investors Lp | 2024-06-30 | 69.2 M | |
| Qvt Financial Lp | 2024-06-30 | 66.7 M |
Roivant Sciences Historical Income Statement
Roivant Stock Against Markets
Roivant Sciences Corporate Management
| Amy Mahery | Chief Officer | Profile | |
| Matthew Gline | CEO Director | Profile | |
| Marianne Romeo | Head Management | Profile | |
| Huafeng Xu | Chief Officer | Profile | |
| Josh Chen | General Counsel | Profile | |
| Matt Maisak | Chief Platforms | Profile | |
| Vivek Ramaswamy | Founder Chairman | Profile |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.